

# Marco Pravetoni

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7677208/publications.pdf>

Version: 2024-02-01

60  
papers

1,997  
citations

185998

28  
h-index

253896

43  
g-index

62  
all docs

62  
docs citations

62  
times ranked

1398  
citing authors

#	ARTICLE	IF	CITATIONS
1	Pharmacological Profiling of Antifentanyl Monoclonal Antibodies in Combination with Naloxone in Pre- and Postexposure Models of Fentanyl Toxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2022, 381, 129-136.	1.3	11
2	Efficacy and Selectivity of Monovalent and Bivalent Vaccination Strategies to Protect against Exposure to Carfentanil, Fentanyl, and Their Mixtures in Rats. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 331-343.	2.5	8
3	Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder. <i>Vaccine</i> , 2022, 40, 3244-3252.	1.7	3
4	Countermeasures for Preventing and Treating Opioid Overdose. <i>Clinical Pharmacology and Therapeutics</i> , 2021, 109, 578-590.	2.3	38
5	Potential unintended consequences of class-wide drug scheduling based on chemical structure: A cautionary tale for fentanyl-related compounds. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108530.	1.6	5
6	A covalent poly(lactic acid) naloxone nanoparticle reduces fentanyl-induced poisoning in rats. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
7	INDâ€ enabling studies of vaccines to treat heroin and oxycodone use disorders. <i>FASEB Journal</i> , 2021, 35, .	0.2	0
8	Fentanyl conjugate vaccine by injected or mucosal delivery with dmlT or LTA1 adjuvants implicates IgA in protection from drug challenge. <i>Npj Vaccines</i> , 2021, 6, 69.	2.9	19
9	Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders. <i>Journal of Immunology</i> , 2021, 207, 860-867.	0.4	5
10	Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats. <i>Human Vaccines and Immunotherapeutics</i> , 2021, 17, 4383-4392.	1.4	3
11	Covalently Loaded Naloxone Nanoparticles as a Long-Acting Medical Countermeasure to Opioid Poisoning. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 1654-1664.	2.5	8
12	Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder. <i>Neuropharmacology</i> , 2021, 195, 108653.	2.0	14
13	A Membrane-Modulated Centrifugal Microdevice for Enzyme-Linked Immunosorbent Assay-Based Detection of Illicit and Misused Drugs. <i>Analytical Chemistry</i> , 2021, 93, 16213-16221.	3.2	7
14	Sex differences in oral oxycodone self-administration and stress-primed reinstatement in rats. <i>Addiction Biology</i> , 2020, 25, e12822.	1.4	34
15	Monoclonal Antibodies Counteract Opioid-Induced Behavioral and Toxic Effects in Mice and Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 375, 469-477.	1.3	33
16	Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 14647-14667.	2.9	25
17	Mechanisms of interleukin 4 mediated increase in efficacy of vaccines against opioid use disorders. <i>Npj Vaccines</i> , 2020, 5, 99.	2.9	13
18	Combining a Candidate Vaccine for Opioid Use Disorders with Extended-Release Naltrexone Increases Protection against Oxycodone-Induced Behavioral Effects and Toxicity. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2020, 374, 392-403.	1.3	9

#	ARTICLE	IF	CITATIONS
19	Is the opioid use disorder epidemic impacting our immunological health?. <i>Brain, Behavior, and Immunity</i> , 2020, 87, 203-204.	2.0	0
20	Interruption of continuous opioid exposure exacerbates drug-evoked adaptations in the mesolimbic dopamine system. <i>Neuropsychopharmacology</i> , 2020, 45, 1781-1792.	2.8	44
21	Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity. <i>Vaccine</i> , 2020, 38, 4704-4712.	1.7	2
22	Covalent Poly(lactic acid) Nanoparticles for the Sustained Delivery of Naloxone. <i>ACS Applied Bio Materials</i> , 2019, 2, 3418-3428.	2.3	18
23	Vaccines to treat opioid use disorders and to reduce opioid overdoses. <i>Neuropsychopharmacology</i> , 2019, 44, 217-218.	2.8	16
24	Development of vaccines to treat opioid use disorders and reduce incidence of overdose. <i>Neuropharmacology</i> , 2019, 158, 107662.	2.0	59
25	Formulation and Characterization of Conjugate Vaccines to Reduce Opioid Use Disorders Suitable for Pharmaceutical Manufacturing and Clinical Evaluation. <i>Molecular Pharmaceutics</i> , 2019, 16, 2364-2375.	2.3	15
26	A Fentanyl Vaccine Alters Fentanyl Distribution and Protects against Fentanyl-Induced Effects in Mice and Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019, 368, 282-291.	1.3	67
27	Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 909-917.	1.4	17
28	Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose. <i>Scientific Reports</i> , 2018, 8, 5508.	1.6	26
29	Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 346-353.	1.3	40
30	Preclinical Efficacy and Characterization of Candidate Vaccines for Treatment of Opioid Use Disorders Using Clinically Viable Carrier Proteins. <i>Molecular Pharmaceutics</i> , 2018, 15, 4947-4962.	2.3	40
31	Oxycodone self-administration in male and female rats. <i>Psychopharmacology</i> , 2017, 234, 977-987.	1.5	77
32	Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse. <i>PLoS ONE</i> , 2017, 12, e0184876.	1.1	47
33	Biologics to treat substance use disorders: Current status and new directions. <i>Human Vaccines and Immunotherapeutics</i> , 2016, 12, 3005-3019.	1.4	37
34	B Cell Mechanisms Underlying Vaccine Efficacy Against Drugs of Abuse. , 2016, , 367-393.		0
35	GIRK Channels Modulate Opioid-Induced Motor Activity in a Cell Type- and Subunit-Dependent Manner. <i>Journal of Neuroscience</i> , 2015, 35, 7131-7142.	1.7	53
36	The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence. <i>Vaccine</i> , 2015, 33, 6332-6339.	1.7	15

#	ARTICLE	IF	CITATIONS
37	The Frequency of Naive and Early-Activated Hapten-Specific B Cell Subsets Dictates the Efficacy of a Therapeutic Vaccine against Prescription Opioid Abuse. <i>Journal of Immunology</i> , 2015, 194, 5926-5936.	0.4	40
38	Effect of Currently Approved Carriers and Adjuvants on the Pre-Clinical Efficacy of a Conjugate Vaccine against Oxycodone in Mice and Rats. <i>PLoS ONE</i> , 2014, 9, e96547.	1.1	45
39	Effects of an Oxycodone Conjugate Vaccine on Oxycodone Self-Administration and Oxycodone-Induced Brain Gene Expression in Rats. <i>PLoS ONE</i> , 2014, 9, e101807.	1.1	61
40	Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse. <i>Journal of Immunological Methods</i> , 2014, 405, 74-86.	0.6	29
41	Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. <i>Vaccine</i> , 2013, 31, 6185-6193.	1.7	37
42	Selective Effects of a Morphine Conjugate Vaccine on Heroin and Metabolite Distribution and Heroin-Induced Behaviors in Rats. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 344, 397-406.	1.3	61
43	Reduced Antinociception of Opioids in Rats and Mice by Vaccination with Immunogens Containing Oxycodone and Hydrocodone Haptens. <i>Journal of Medicinal Chemistry</i> , 2013, 56, 915-923.	2.9	59
44	Immunogenicity of Individual Vaccine Components in a Bivalent Nicotine Vaccine Differ According to Vaccine Formulation and Administration Conditions. <i>PLoS ONE</i> , 2013, 8, e82557.	1.1	26
45	High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. <i>Vaccine</i> , 2012, 31, 159-164.	1.7	52
46	An Oxycodone Conjugate Vaccine Elicits Drug-Specific Antibodies that Reduce Oxycodone Distribution to Brain and Hot-Plate Analgesia. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2012, 341, 225-232.	1.3	73
47	Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. <i>Vaccine</i> , 2012, 30, 4617-4624.	1.7	77
48	Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. <i>Biochemical Pharmacology</i> , 2012, 83, 543-550.	2.0	57
49	Enhanced attenuation of nicotine discrimination in rats by combining nicotine-specific antibodies with a nicotinic receptor antagonist. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 102, 157-162.	1.3	12
50	Vaccination against nicotine alters the distribution of nicotine delivered via cigarette smoke inhalation to rats. <i>Biochemical Pharmacology</i> , 2011, 81, 1164-1170.	2.0	30
51	Altered neurotransmission in the mesolimbic reward system of <i>Girk<sup>0/0</sup></i> mice. <i>Journal of Neurochemistry</i> , 2010, 114, 1487-1497.	2.1	42
52	R7BP Complexes With RGS9-2 and RGS7 in the Striatum Differentially Control Motor Learning and Locomotor Responses to Cocaine. <i>Neuropsychopharmacology</i> , 2010, 35, 1040-1050.	2.8	46
53	Behavioral characterization of mice lacking GIRK/Kir3 channel subunits. <i>Genes, Brain and Behavior</i> , 2008, 7, 523-531.	1.1	80
54	Absence and Rescue of Morphine Withdrawal in GIRK/Kir3 Knock-out Mice. <i>Journal of Neuroscience</i> , 2008, 28, 4069-4077.	1.7	62

#	ARTICLE	IF	CITATIONS
55	Predisposition to late-onset obesity in GIRK4 knockout mice. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8148-8153.	3.3	42
56	Expression and Localization of RGS9-2/G 5/R7BP Complex In Vivo Is Set by Dynamic Control of Its Constitutive Degradation by Cellular Cysteine Proteases. Journal of Neuroscience, 2007, 27, 14117-14127.	1.7	60
57	Inhibition of Nitric Oxide Synthase Enhances Cocaine's Developmental Toxicity: Vascular and CNS Effects. Neuropsychopharmacology, 2007, 32, 940-945.	2.8	3
58	Vasoconstriction Caused by Cocaine is Enhanced by Sodium Salicylate: Is Inducible Nitric Oxide Synthase mRNA Related?. Neuropsychopharmacology, 2004, 29, 1294-1300.	2.8	2
59	Quantification of Housekeeping Transcript Levels During the Development of Bovine Preimplantation Embryos1. Biology of Reproduction, 2002, 67, 1465-1472.	1.2	182
60	Preclinical Efficacy and Selectivity of Vaccines Targeting Fentanyl, Alfentanil, Sufentanil, and Acetylfentanyl in Rats. ACS Omega, 0, , .	1.6	10